These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 31718458)

  • 41. A decision rule for sequential monitoring of clinical trials with a primary and supportive outcome.
    Zhao Y; Grambsch PM; Neaton JD
    Clin Trials; 2007; 4(2):140-53. PubMed ID: 17456513
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Group sequential monitoring of distribution-free analyses of repeated measures.
    Lachin JM
    Stat Med; 1997 Mar; 16(6):653-68. PubMed ID: 9131754
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Symmetric group sequential test designs.
    Emerson SS; Fleming TR
    Biometrics; 1989 Sep; 45(3):905-23. PubMed ID: 2675998
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Designing historical control studies with survival endpoints using exact statistical inference.
    Han G
    Pharm Stat; 2021 Jan; 20(1):4-14. PubMed ID: 32743949
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A computer program for designing clinical trials with arbitrary survival curves and group sequential testing.
    Halpern J; Brown BW
    Control Clin Trials; 1993 Apr; 14(2):109-22. PubMed ID: 8500301
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Implementation of group sequential logrank tests in a maximum duration trial.
    Lan KK; Lachin JM
    Biometrics; 1990 Sep; 46(3):759-70. PubMed ID: 2242413
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A two-stage group-sequential design for delayed treatment responses with the possibility of trial restart.
    Schüürhuis S; Konietschke F; Kunz CU
    Stat Med; 2024 May; 43(12):2368-2388. PubMed ID: 38564226
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Reducing overestimation of the treatment effect by interim analysis when designing clinical trials.
    Shimura M
    J Clin Pharm Ther; 2019 Apr; 44(2):243-248. PubMed ID: 30414384
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Bayesian analysis of quantal bioassay experiments incorporating historical controls via Bayes factors.
    León Novelo LG; Womack A; Zhu H; Wu X
    Stat Med; 2017 May; 36(12):1907-1923. PubMed ID: 28106916
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Monitoring multi-armed trials.
    Proschan MA; Follmann DA; Geller NL
    Stat Med; 1994 Jul 15-30; 13(13-14):1441-52. PubMed ID: 7973223
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Information time scales for interim analyses of randomized clinical trials.
    Freidlin B; Othus M; Korn EL
    Clin Trials; 2016 Aug; 13(4):391-9. PubMed ID: 27136947
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Online control of the False Discovery Rate in group-sequential platform trials.
    Zehetmayer S; Posch M; Koenig F
    Stat Methods Med Res; 2022 Dec; 31(12):2470-2485. PubMed ID: 36189481
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A group sequential, response-adaptive design for randomized clinical trials.
    Karrison TG; Huo D; Chappell R
    Control Clin Trials; 2003 Oct; 24(5):506-22. PubMed ID: 14500050
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Optimality criteria for futility stopping boundaries for group sequential designs with a continuous endpoint.
    Li X; Herrmann C; Rauch G
    BMC Med Res Methodol; 2020 Nov; 20(1):274. PubMed ID: 33153438
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Group sequential testing for cluster randomized trials with time-to-event endpoint.
    Li J; Jung SH
    Biometrics; 2022 Dec; 78(4):1353-1364. PubMed ID: 34076257
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Multi-arm group sequential designs with a simultaneous stopping rule.
    Urach S; Posch M
    Stat Med; 2016 Dec; 35(30):5536-5550. PubMed ID: 27550822
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sequential methods and group sequential designs for comparative clinical trials.
    Sébille V; Bellissant E
    Fundam Clin Pharmacol; 2003 Oct; 17(5):505-16. PubMed ID: 14703713
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Design, data monitoring, and analysis of clinical trials with co-primary endpoints: A review.
    Hamasaki T; Evans SR; Asakura K
    J Biopharm Stat; 2018; 28(1):28-51. PubMed ID: 29083951
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Conditional power calculations for early acceptance of H0 embedded in sequential tests.
    Betensky RA
    Stat Med; 1997 Feb; 16(4):465-77. PubMed ID: 9044533
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Coupled error spending functions for parallel bivariate sequential tests.
    Cook RJ
    Biometrics; 1996 Jun; 52(2):442-50. PubMed ID: 8672698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.